Hierarchical mesoporous silicon and albumin composite microparticles delivering DOX and FU for liver cancer treatment

被引:3
|
作者
Xu, Tianyuan [1 ,2 ,3 ,4 ,5 ]
Fan, Lu [4 ]
Wang, Li [4 ]
Ren, Haozhen [3 ]
Zhang, Qingfei [1 ,2 ,4 ,6 ]
Sun, Weijian [1 ,2 ]
机构
[1] Wenzhou Med Univ, Affiliated Hosp 2, Dept Gastrointestinal Surg, Wenzhou 325027, Peoples R China
[2] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou 325027, Peoples R China
[3] Nanjing Univ, Nanjing Drum Tower Hosp, Med Sch, Dept Hepatobiliary Surg, Nanjing 210008, Peoples R China
[4] Univ Chinese Acad Sci, Wenzhou Inst, Wenzhou 325001, Zhejiang, Peoples R China
[5] Guangxi Med Univ, Natl Ctr Int Res Biotargeting Theranost, Collaborat Innovat Ctr Targeting Tumor Diag & Ther, State Key Lab Targeting Oncol,Guangxi Key Lab Biot, Nanning 530021, Guangxi, Peoples R China
[6] Wenzhou Med Univ, Affiliated Hosp 2, Key Lab Pediat Hematol & Oncol Dis Wenzhou, Wenzhou 325027, Peoples R China
基金
中国国家自然科学基金;
关键词
Bovine serum albumin; Microfluidics; Microparticle; Liver cancer; Mesoporous silicon nanoparticle; DRUG-RELEASE; NANOPARTICLES; MICROFLUIDICS;
D O I
10.1016/j.ijbiomac.2024.131732
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Drug delivery systems based on hydrogel microcarriers have shown enormous achievements in tumor treatment. Current research direction mainly concentrated on the improvement of the structure and function of the microcarriers to effectively deliver drugs for enhanced cancer treatment with decreased general toxicity. Herein, we put forward novel hierarchical mesoporous silicon nanoparticles (MSNs) and bovine serum albumin (BSA) composite microparticles (MPMSNs@DOX/FU) delivering doxorubicin (DOX) and 5-fluorouracil (FU) for effective tumor therapy with good safety. The DOX and FU could be efficiently loaded in the MSNs, which were further encapsulated into methacrylate BSA (BSAMA) microparticles by applying a microfluidic technique. When transported to the tumor area, DOX and FU will be persistently released from the MPMSNs@DOX/FU and kept locally to lessen general toxicity. Based on these advantages, MPMSNs@DOX/FU could observably kill liver cancer cells in vitro, and evidently suppress the tumor development of liver cancer nude mice model in vivo. These results suggest that such hierarchical hydrogel microparticles are perfect candidates for liver cancer treatment, holding promising expectations for impactful cancer therapy.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Clinical application of gelatin sponge microparticles combined with pirarubicin for hepatic transcatheter arterial chemoembolization in breast cancer liver metastasis treatment: results of a single-center long-term study
    Zhao, Guang Sheng
    Liu, Song
    Liu, Ying
    Ma, Jian
    Wang, Ruo Yu
    Bian, Jie
    Zhou, Jun
    Wu, Jian Lin
    Zhang, Yue Wei
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2021, 19 (01)
  • [42] Clinical application of gelatin sponge microparticles combined with pirarubicin for hepatic transcatheter arterial chemoembolization in breast cancer liver metastasis treatment: results of a single-center long-term study
    Guang Sheng Zhao
    Song Liu
    Ying Liu
    Jian Ma
    Ruo Yu Wang
    Jie Bian
    Jun Zhou
    Jian Lin Wu
    Yue Wei Zhang
    World Journal of Surgical Oncology, 19
  • [43] Resectability of liver metastases (LM) in patients with advanced colorectal cancer (ACRA) after treatment with the combination of oxaliplatin (OXA), irinotecan (IRI) and 5FU.: Final results of a phase II study.
    Abad, A
    Antón, A
    Massuti, B
    Rivera, F
    Marcuello, E
    Navarro, M
    Tabernero, J
    Aranda, E
    Carrato, A
    Díaz-Rubio, E
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 275S - 275S
  • [44] Capecitabine but not 5-FU worsened hepatosplenomegaly and liver function when used with oxaliplatin and cetuximab as first-line treatment in K-ras wild-type metastatic colorectal cancer.
    Lee, Victor H. F.
    Fang, Weijia
    Lam, Ka On
    Choi, Cheuk Wai
    Ng, Sherry C. Y.
    Ho, Patty P. Y.
    Ho, Garrett C. L.
    Cheng, Thomas K. C.
    Liu, Rico K. Y.
    Leung, To Wai
    Kwong, Dora Lai Wan
    Zheng, Shusen
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [45] Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial
    Skof, Erik
    Rebersek, Martina
    Hlebanja, Zvezdana
    Ocvirk, Janja
    BMC CANCER, 2009, 9
  • [46] Photothermal treatment of liver cancer with albumin-conjugated gold nanoparticles initiates Golgi Apparatus-ER dysfunction and caspase-3 apoptotic pathway activation by selective targeting of Gp60 receptor
    Mocan, Lucian
    Matea, Cristian
    Tabaran, Flaviu A.
    Mosteanu, Ofelia
    Pop, Teodora
    Mocan, Teodora
    Iancu, Cornel
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2015, 10 : 5435 - 5445
  • [47] Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial
    Erik Skof
    Martina Rebersek
    Zvezdana Hlebanja
    Janja Ocvirk
    BMC Cancer, 9
  • [48] Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2+/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49
    Pernot, Simon
    Pellerin, Olivier
    Mineur, Laurent
    Monterymard, Carole
    Smith, Denis
    Lapuyade, Bruno
    Gallois, Claire
    Tougeron, David
    Thirot-Bidault, Anne
    Audemar, Franck
    Simon, Mireille
    Lecaille, Cedric
    Louafi, Sami
    Lepage, Come
    Ducreux, Michel
    Taieb, Julien
    Akouz, Faiza Khemissa
    De Baere, Thierry
    DIGESTIVE AND LIVER DISEASE, 2022, 54 (03) : 324 - 330
  • [49] Clinical application of gelatin sponge microparticles-transcatheter arterial chemoembolization combined with synchronous antigen-presenting dendritic cell sequential reinfusion for treatment of advanced large liver cancer A single-center, prospective, non-randomized, controlled trial
    Zhao, Guang Sheng
    Liu, Song
    Liu, Ying
    Li, Chuang
    Wang, Ruo Yu
    Bian, Jie
    Zhu, Rui Ping
    Zhou, Jun
    Zhang, Yue Wei
    MEDICINE, 2022, 101 (08) : E28803
  • [50] Photothermal treatment of liver cancer with albumin-conjugated gold nanoparticles initiates Golgi Apparatus-ER dysfunction and caspase-3 apoptotic pathway activation by selective targeting of Gp60 receptor (vol 10, pg 5435, 2015)
    Mocan, L.
    Matea, C.
    Tabaran, F. A.
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2016, 11 : 1025 - 1025